Tag: SGLT-2 inhibitors

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...
1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure in patients with diabetes and recent worsening heart failure compared to placebo. 2. Sotagliflozin was shown to be similar in the percentage of patients with adverse...
1. The use of sodium-glucose cotransporter-2 (SGLT-2i) increased study participants’ risk of diabetic ketoacidosis (DKA) hospital presentations when compared to dipeptidyl peptidase 4 inhibitors 2. Amongst all the sodium-glucose cotransporter-2 inhibitors included in the study, canagliflozin demonstrated the highest risk of DKA hospital presentations Evidence Rating Level: 2 (Good) Study Rundown: Sodium-glucose...
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to DPP-4 inhibitors or GLP-1 agonists. Evidence Rating Level: 2 (Good) Study Rundown: The sodium glucose cotransporter-2 (SGLT-2) inhibitors are a newer class of diabetic medications that act by inhibiting glucose reabsorption in...
1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to DPP-4 inhibitors or GLP-1 agonists. Evidence Rating Level: 2 (Good) Study Rundown: The sodium glucose cotransporter-2 (SGLT-2) inhibitors are a newer class of diabetic medications that act by inhibiting glucose reabsorption...